Agios Pharmaceuticals Inc (NASDAQ:AGIO) Receives Consensus Rating of “Hold” from Brokerages

Agios Pharmaceuticals Inc (NASDAQ:AGIO) has received an average recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $80.00.

AGIO has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Green Brick Partners from a “sell” rating to a “hold” rating in a research note on Thursday, April 25th. ValuEngine cut Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th. Royal Bank of Canada increased their price target on Victory Capital to $19.00 and gave the company an “outperform” rating in a research note on Thursday, May 16th. Piper Jaffray Companies increased their price target on Marvell Technology Group from $22.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Finally, BidaskClub upgraded WhiteHorse Finance from a “sell” rating to a “hold” rating in a research note on Thursday, July 18th.

Shares of Agios Pharmaceuticals stock traded up $0.24 on Friday, reaching $46.94. 374,844 shares of the company were exchanged, compared to its average volume of 514,240. Agios Pharmaceuticals has a one year low of $41.63 and a one year high of $89.50. The firm has a market cap of $2.74 billion, a P/E ratio of -7.78 and a beta of 2.22. The company has a quick ratio of 6.86, a current ratio of 6.89 and a debt-to-equity ratio of 0.11. The firm’s 50-day moving average is $48.07.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. Agios Pharmaceuticals had a negative return on equity of 48.19% and a negative net margin of 300.63%. The company had revenue of $30.20 million for the quarter, compared to analysts’ expectations of $22.69 million. During the same quarter in the prior year, the business posted ($1.63) EPS. The business’s revenue was up 243.2% compared to the same quarter last year. Analysts anticipate that Agios Pharmaceuticals will post -6.76 EPS for the current year.

A number of hedge funds have recently bought and sold shares of AGIO. Wealthstreet Investment Advisors LLC grew its holdings in shares of Agios Pharmaceuticals by 0.9% during the 1st quarter. Wealthstreet Investment Advisors LLC now owns 29,415 shares of the biopharmaceutical company’s stock worth $1,984,000 after purchasing an additional 250 shares in the last quarter. Advisor Group Inc. grew its holdings in shares of Agios Pharmaceuticals by 33.1% during the 4th quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 297 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Agios Pharmaceuticals by 0.4% during the 1st quarter. California State Teachers Retirement System now owns 80,018 shares of the biopharmaceutical company’s stock worth $5,396,000 after purchasing an additional 334 shares in the last quarter. Oppenheimer & Co. Inc. grew its holdings in shares of Agios Pharmaceuticals by 0.8% during the 1st quarter. Oppenheimer & Co. Inc. now owns 64,127 shares of the biopharmaceutical company’s stock worth $4,325,000 after purchasing an additional 535 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of Agios Pharmaceuticals by 1.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 74,257 shares of the biopharmaceutical company’s stock worth $5,008,000 after purchasing an additional 860 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Further Reading: How is a Moving Average Calculated?

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.